This document is scheduled to be published in the Federal Register on 02/24/2016 and available online at http://federalregister.gov/a/2016-03782, and on FDsys.gov

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel

Cystic Fibrosis Transmembrane Conductance Regulator - Directed

Therapeutics

Date: March 16, 2016

Time: 1:00 PM to 4:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

6701 Rockledge Drive, Room 7185

Bethesda, MD 20892

(Telephone Conference Call)

Contact Person: Kristen Page, PHD

Scientific Review Officer

Office of Scientific Review/DERA

National Heart, Lung, and Blood Institute

6701 Rockledge Drive

Room 7185

Bethesda, MD 20892

301-435-0725

kristen.page@nih.gov

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: February 18, 2016

Michelle Trout, Program Analyst,

Office of Federal Advisory Committee Policy.

[FR Doc. 2016-03782 Filed: 2/23/2016 8:45 am; Publication Date: 2/24/2016]